SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Boman Kurt) "

Sökning: WFRF:(Boman Kurt)

  • Resultat 1-10 av 86
  • [1]234567...9Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Agewall, Stefan, et al. (författare)
  • Politik mot hjärtinfarkt
  • 2013
  • Ingår i: Läkartidningen. - 0023-7205. ; 110:13-14, s. 664
  • Tidskriftsartikel (refereegranskat)
  •  
2.
  • Almroth, Henrik, et al. (författare)
  • Atorvastatin and persistent atrial fibrillation following cardioversion : a randomized placebo-controlled multicentre study
  • 2009
  • Ingår i: European Heart Journal. - Philadelphia : W.B. Saunders. - 0195-668X. ; 30:7, s. 827-833
  • Tidskriftsartikel (refereegranskat)abstract
    • AIMS: To evaluate the effect of atorvastatin in achieving stable sinus rhythm (SR) 30 days after electrical cardioversion (CV) in patients with persistent atrial fibrillation (AF). METHODS AND RESULTS: The study included 234 patients. The patients were randomized to treatment with atorvastatin 80 mg daily (n = 118) or placebo (n = 116) in a prospective, double-blinded fashion. Treatment was initiated 14 days before CV and was continued 30 days after CV. The two groups were well-balanced with respect to baseline characteristics. Mean age was 65 +/- 10 years, 76% of the patients were male and 4% had ischaemic heart disease. Study medication was well-tolerated in all patients but one. Before primary endpoint 12 patients were excluded. In the atorvastatin group 99 patients (89%) converted to SR at electrical CV compared with 95 (86%) in the placebo group (P = 0.42). An intention-to-treat analysis with the available data, by randomization group, showed that 57 (51%) in the atorvastatin group and 47 (42%) in the placebo group were in SR 30 days after CV (OR 1.44, 95%CI 0.85-2.44, P = 0.18). CONCLUSION: Atorvastatin was not statistically superior to placebo with regards to maintaining SR 30 days after CV in patients with persistent AF.
  •  
3.
  • Andersson, Jonas, 1977-, et al. (författare)
  • C-reactive protein is a determinant of first-ever stroke: prospective nested case-referent study.
  • 2009
  • Ingår i: Cerebrovascular diseases (Basel, Switzerland). - 1421-9786. ; 27:6, s. 544
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND AND PURPOSE: C-reactive protein (CRP) is a determinant of stroke, but there are no prospective studies on CRP and first ischemic stroke divided into etiologic subtypes. Our primary aim was to study CRP as a determinant of ischemic stroke, classified according to Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria, and intracerebral hemorrhage (ICH) in a prospective study. A secondary aim was to study the relationship between the 1444C>T polymorphism, plasma levels of CRP and stroke.METHODS: The study was a prospective population-based case-referent study nested within the Northern Sweden Cohorts. We defined 308 cases of ischemic stroke and 61 ICH. Two controls for each case were defined from the same cohort.RESULTS: The OR for the highest (>3 mg/l) versus lowest group (<1 mg/l) of CRP was 2.58 (95% CI 1.74-3.84) for ischemic stroke and 1.63 (95% CI 0.67-3.93) for ICH. In a multivariate model including traditional risk factors, CRP remained associated with ischemic stroke (OR 2.06; 95% CI 1.29-3.29). Small-vessel disease was associated with CRP in the multivariate model (OR 3.88; 95% CI 1.10-13.7). The CRP 1444 (CC/CT vs. TT) polymorphism was associated with plasma levels of CRP but neither with ischemic stroke nor with ICH.CONCLUSIONS: This prospective population-based study shows that CRP is significantly associated with the risk of having a first ischemic stroke, especially for small-vessel disease. No significant associations were found between the CRP 1444C>T polymorphism and any stroke subtype.
  •  
4.
  • Andersson, Jonas, 1977-, et al. (författare)
  • Effects of heavy endurance physical exercise on inflammatory markers in non-athletes
  • 2010
  • Ingår i: Atherosclerosis. - 0021-9150. ; 209:2, s. 601-605
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVES: Physical activity has beneficial effects on cardiovascular disease but the mechanisms are still somewhat unclear. One possible pathway may be through the anti-inflammatory effects attributed to regular physical activity. Our primary aim was to study the effects of endurance physical exercise on C-reactive protein (CRP), Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNFalpha) during the acute and recovery phases. Secondarily, we studied the impact of diet on these inflammatory markers.METHODS: Twenty men, aged 18-55 years, participated in a 14 days cross-country skiing tour. They traveled 12-30km per day corresponding to about 10h of heavy physical activity. The participants were randomized to a diet with either 30 or 40% of energy derived from fat. Inflammatory variables were analysed at week 0, after 1 and 2 weeks and during the recovery phase at week 6 and 8.RESULTS: CRP and TNFalpha increased significantly during the two weeks of exercise (1.4-5.0mg/l, p=0.00 and 6.8-8.4pg/ml, p=0.00). CRP levels were significantly lower during recovery (median 0.7mg/l) compared to baseline (median 1.4mg/l) and did not correlate to metabolic variables. There were no significant changes in IL-6 levels during the study period. For dietary groups significant CRP changes were observed only in the high fat group during recovery.CONCLUSIONS: CRP and TNFalpha increased significantly but reacted differently during heavy physical activity while there seemed to be no significant changes in IL-6. No significant differences regarding inflammatory variables were found between the dietary groups.
  •  
5.
  • Andersson, Jonas, et al. (författare)
  • Markers of fibrinolysis as predictors for maintenance of sinus rhythm after electrical cardioversion
  • 2011
  • Ingår i: Thrombosis Research. - 0049-3848. ; 127:3, s. 189-192
  • Tidskriftsartikel (refereegranskat)abstract
    • No fibrinolytic component alone was found to be a predictor of recurrence of atrial fibrillation. In multivariate models lower PAI-1 mass was associated with sinus rhythm even after adjusting for CRP, markers of the metabolic syndrome and treatment with atorvastatin. Our findings suggest a patophysiological link between AF and PAI-1 mass but the relation to inflammation remains unclear.
  •  
6.
  • Bang, Casper N., et al. (författare)
  • Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis : The Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study
  • 2012
  • Ingår i: American Heart Journal. - Elsevier. - 0002-8703. ; 163:4, s. 690-696
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Lipid-lowering drugs, particularly statins, have anti-inflammatory and antioxidant properties that may prevent atrial fibrillation (AF). This effect has not been investigated on new-onset AF in asymptomatic patients with aortic stenosis (AS). Methods Asymptomatic patients with mild-to-moderate AS (n = 1,421) were randomized (1: 1) to double-blind simvastatin 40 mg and ezetimibe 10 mg combination or placebo and followed up for a mean of 4.3 years. The primary end point was the time to new-onset AF adjudicated by 12-lead electrocardiogram at a core laboratory reading center. Secondary outcomes were the correlates of new-onset AF with nonfatal nonhemorrhagic stroke and a combined end point of AS-related events. Results During the course of the study, new-onset AF was detected in 85 (6%) patients (14.2/1,000 person-years of follow-up). At baseline, patients who developed AF were, compared with those remaining in sinus rhythm, older and had a higher left ventricular mass index a smaller aortic valve area index. Treatment with simvastatin and ezetimibe was not associated with less new-onset AF (odds ratio 0.89 [95% CI 0.57-1.97], P = .717). In contrast, age (hazard ratio [HR] 1.07 [95% CI 1.05-1.10], P < .001) and left ventricular mass index (HR 1.01 [95% CI 1.01-1.02], P < .001) were independent predictors of new-onset AF. The occurrence of new-onset AF was independently associated with 2-fold higher risk of AS-related outcomes (HR 1.65 [95% CI 1.02-2.66], P = .04) and 4-fold higher risk of nonfatal nonhemorrhagic stroke (HR 4.04 [95% CI 1.18-13.82], P = .03). Conclusions Simvastatin and ezetimibe were not associated with less new-onset AF. Older age and greater left ventricular mass index were independent predictors of AF development. New-onset AF was associated with a worsening of prognosis. (Am Heart J 2012;163:690-6.)
  •  
7.
  • Bang, Casper N., et al. (författare)
  • Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients : the Losartan Intervention For Endpoint reduction in hypertension study
  • 2013
  • Ingår i: Journal of Hypertension. - Lippincott Williams & Wilkins. - 0263-6352. ; 31:10, s. 2060-2068
  • Tidskriftsartikel (refereegranskat)abstract
    • Background:Left ventricular hypertrophy [LVH, high left ventricular mass (LVM)] is traditionally classified as concentric or eccentric based on left ventricular relative wall thickness. We evaluated left ventricular systolic function in a new four-group LVH classification based on left ventricular dilatation [high left ventricular end-diastolic volume (EDV) index and concentricity (LVM/EDV(2/3))] in hypertensive patients.Methods and results:Nine hundred thirty-nine participants in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy had measurable LVM at enrolment. Patients with LVH (LVM/body surface area 116g/m(2) in men and 96g/m(2) in women) were divided into four groups; eccentric nondilated' (normal LVM/EDV and EDV), eccentric dilated' (increased EDV, normal LVM/EDV), concentric nondilated' (increased LVM/EDV with normal EDV), and concentric dilated' (increased LVM/EDV and EDV) and compared to patients with normal LVM. At baseline, 12% had eccentric nondilated, 20% eccentric dilated, 29% concentric nondilated, and 14% concentric dilated LVH, with normal LVM in 25%. Compared with the concentric nondilated LVH group, those with concentric dilated LVH had significantly lower pulse pressure/stroke index and ejection fraction; higher LVM index, stroke volume, cardiac output, left ventricular midwall shortening, left atrial volume and isovolumic relaxation time; and more had segmental wall motion abnormalities (all P<0.05). Similar differences existed between patients with eccentric dilated and those with eccentric nondilated LVH (all P<0.05). Compared with patients with normal LVM, the eccentric nondilated had higher LV stroke volume, pulse pressure/stroke index, Cornell voltage product and SBP, and lower heart rate and fewer were African-American (all P<0.05).Conclusion:The new four-group classification of LVH identifies dilated subgroups with reduced left ventricular function among patients currently classified with eccentric or concentric LVH.
  •  
8.
  •  
9.
  • Bergström, Erik, et al. (författare)
  • [Do better next time]
  • 2009
  • Ingår i: Läkartidningen. - 0023-7205. ; 106:8, s. 527
  • Tidskriftsartikel (övrigt vetenskapligt)
  •  
10.
  • Boman, Kurt, et al. (författare)
  • Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure--a COMET substudy
  • 2010
  • Ingår i: Thrombosis Research. - 0049-3848. ; 125:2, s. 46-50
  • Tidskriftsartikel (refereegranskat)abstract
    • INTRODUCTION: In COMET (Carvedilol or Metoprolol European Trial), carvedilol reduced mortality compared with metoprolol in patients with chronic heart failure. We hypothesized that carvedilol might have greater effects on endothelial derived haemostatic factors than metoprolol. We aimed to study the effects of carvedilol or metoprolol on tissue plasminogen activator (tPA), its inhibitor PAI-1 and Von Willebrand factor (VWF) in patients with heart failure. MATERIAL AND METHODS: We recruited 260 patients (134 on carvedilol, 126 on metoprolol), mean age 66 years and 84% of them men. Plasma mass concentrations of tPA and PAI-1and percent of VWF were measured at baseline and after one and two years of treatment. RESULTS: Plasma tPA, PAI-1 and VWF were similar between treatment groups at baseline and no significant differences between groups emerged after one or two years of treatment. In paired analyses in patients assigned to carvedilol, median PAI-1 level decreased from 37.2 to 32.1 microg/l at two years (p=0.034) and of VWF decreased from baseline to one year (240 vs. 218%, p=0.023) in patients assigned to carvedilol but were not reduced at any time in patients assigned to metoprolol. Plasma tPA increased over time in both treatment groups (p=0.013 and 0.027 respectively). CONCLUSION: We found no significant difference in the effects of carvedilol or metoprolol on tPA, PAI-1 and VWF. Comparison over time within treatment groups suggested that PAI-1 and VWF might have declined on carvedilol but not on metoprolol. Our hypothesis is not proved but this may reflect an inadequate sample size rather than lack of an effect.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 86
  • [1]234567...9Nästa
Åtkomst
fritt online (8)
Typ av publikation
tidskriftsartikel (81)
konferensbidrag (2)
annan publikation (2)
bokkapitel (1)
Typ av innehåll
refereegranskat (80)
övrigt vetenskapligt (6)
Författare/redaktör
Boman, Kurt (84)
Wachtell, Kristian (19)
Willenheimer, Ronnie (18)
Gerdts, Eva (18)
Jansson, Jan-Håkan, (17)
Gohlke-Baerwolf, Chr ... (14)
visa fler...
Egstrup, Kenneth (12)
Ray, Simon (12)
Rossebo, Anne B. (11)
Hallmans, Göran (9)
Pedersen, Terje R, (9)
Johansson, Lars, (8)
Holme, Ingar (8)
Nilsson, Torbjörn K (8)
Nienaber, Christoph ... (7)
Devereux, Richard B. (7)
Kesaniemi, Y Antero (7)
Malbecq, William (7)
Dahlström, Ulf, (6)
Strandberg, Gunilla, (6)
Weinehall, Lars (6)
Greve, Anders M. (6)
Kober, Lars (6)
Brännström, Margaret ... (6)
Brudi, Philippe (6)
Skjaerpe, Terje (6)
Chambers, John B. (6)
Nilsson, Torbjörn, (5)
Olofsson, Mona, (5)
Brulin, Christine, (4)
Eliasson, Mats, (4)
Stenlund, Hans (4)
Nieminen, Markku S. (4)
Brodin, Lars-Åke, (4)
Hagerman, Inger (4)
Hägglund, Lena, (4)
Jander, Nikolaus (4)
Minners, Jan (4)
Englund, Anders (3)
Johansson, Ingegerd (3)
Söderberg, Stefan, (3)
Hallmans, Göran, 194 ... (3)
Lundman, Berit (3)
Almroth, Henrik (3)
Höglund, Niklas, (3)
Tornvall, Per (3)
Näslund, Ulf (3)
Nilsson, Johan (3)
Norberg, Margareta (3)
Ekman, Inger, (3)
visa färre...
Lärosäte
Umeå universitet (66)
Lunds universitet (22)
Göteborgs universitet (9)
Uppsala universitet (7)
Örebro universitet (6)
Linköpings universitet (3)
visa fler...
Ersta Sköndal högskola (2)
Linnéuniversitetet (1)
visa färre...
Språk
Engelska (76)
Svenska (10)
Ämne (HSV)
Medicin och hälsovetenskap (50)
Naturvetenskap (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy